S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

JNJ Johnson and Johnson

155.91

0.56 (0.36%)

Apr 29 2025 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

12/04/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Bradley Camilo, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for William N. Hait

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2025 to Apr 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2024 to Apr 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson News

Form 4 - Statement of changes in beneficial ownership of securities
Monday 28 April 2025 (1 day ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 28 April 2025 (1 day ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 28 April 2025 (1 day ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 28 April 2025 (1 day ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 28 April 2025 (1 day ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 28 April 2025 (1 day ago) • Edgar (US Regulatory)

Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
Monday 28 April 2025 (1 day ago) • Business Wire

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
Saturday 26 April 2025 (4 days ago) • PR Newswire (US)

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
Saturday 26 April 2025 (4 days ago) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 23 April 2025 (6 days ago) • Edgar (US Regulatory)

Form PX14A6G - Notice of exempt solicitation submitted by non-management
Wednesday 23 April 2025 (7 days ago) • Edgar (US Regulatory)

Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
Monday 21 April 2025 (1 week ago) • PR Newswire (US)

More Johnson and Johnson News Articles

Mayr Melnhof Karton

SPDR Portfolio High Yiel...

Dorsey Wright Technical ...

Green Shift Commodities

Hermez Network Token

Direxion Daily South Kor...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions